175 related articles for article (PubMed ID: 26785154)
1. Selective small molecule angiotensin II type 2 receptor antagonists for neuropathic pain: preclinical and clinical studies.
Smith MT; Anand P; Rice ASC
Pain; 2016 Feb; 157 Suppl 1():S33-S41. PubMed ID: 26785154
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II type 2-receptor: new clinically validated target in the treatment of neuropathic pain.
Rice AS; Smith MT
Clin Pharmacol Ther; 2015 Feb; 97(2):128-30. PubMed ID: 25670516
[TBL] [Abstract][Full Text] [Related]
3. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.
Rice ASC; Dworkin RH; McCarthy TD; Anand P; Bountra C; McCloud PI; Hill J; Cutter G; Kitson G; Desem N; Raff M;
Lancet; 2014 May; 383(9929):1637-1647. PubMed ID: 24507377
[TBL] [Abstract][Full Text] [Related]
4. Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain.
Smith MT; Muralidharan A
Expert Opin Ther Targets; 2015 Jan; 19(1):25-35. PubMed ID: 25315162
[TBL] [Abstract][Full Text] [Related]
5. Analgesic efficacy and mode of action of a selective small molecule angiotensin II type 2 receptor antagonist in a rat model of prostate cancer-induced bone pain.
Muralidharan A; Wyse BD; Smith MT
Pain Med; 2014 Jan; 15(1):93-110. PubMed ID: 24433468
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation.
Shepherd AJ; Rice AS; Smith MT
Curr Opin Pharmacol; 2023 Dec; 73():102415. PubMed ID: 38041933
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies.
Anand U; Yiangou Y; Sinisi M; Fox M; MacQuillan A; Quick T; Korchev YE; Bountra C; McCarthy T; Anand P
Mol Pain; 2015 Jun; 11():38. PubMed ID: 26111701
[TBL] [Abstract][Full Text] [Related]
8. Small molecule angiotensin II type 2 receptor (AT₂R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats.
Smith MT; Wyse BD; Edwards SR
Pain Med; 2013 May; 14(5):692-705. PubMed ID: 23489258
[TBL] [Abstract][Full Text] [Related]
9. Emerging therapies for neuropathic pain: new molecules or new indications for old treatments?
Bouhassira D; Attal N
Pain; 2018 Mar; 159(3):576-582. PubMed ID: 29447137
[TBL] [Abstract][Full Text] [Related]
10. A small molecule angiotensin II type 2 receptor (AT₂R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen-activated protein kinase (MAPK) and p44/p42 MAPK activation in the dorsal root ganglia.
Smith MT; Woodruff TM; Wyse BD; Muralidharan A; Walther T
Pain Med; 2013 Oct; 14(10):1557-68. PubMed ID: 23742186
[TBL] [Abstract][Full Text] [Related]
11. Development of EMA401 as an orally-administered, highly-selective angiotensin II type 2 receptor antagonist for the treatment of neuropathic pain.
McCarthy T
J Peripher Nerv Syst; 2014 Oct; 19 Suppl 2():S13-4. PubMed ID: 25269730
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of EMA401 in peripheral neuropathic pain: results of 2 randomised, double-blind, phase 2 studies in patients with postherpetic neuralgia and painful diabetic neuropathy.
Rice ASC; Dworkin RH; Finnerup NB; Attal N; Anand P; Freeman R; Piaia A; Callegari F; Doerr C; Mondal S; Narayanan N; Ecochard L; Flossbach Y; Pandhi S
Pain; 2021 Oct; 162(10):2578-2589. PubMed ID: 33675631
[TBL] [Abstract][Full Text] [Related]
13. Oxycodone for neuropathic pain and fibromyalgia in adults.
Gaskell H; Moore RA; Derry S; Stannard C
Cochrane Database Syst Rev; 2014 Jun; (6):CD010692. PubMed ID: 24956205
[TBL] [Abstract][Full Text] [Related]
14. Methadone for neuropathic pain in adults.
McNicol ED; Ferguson MC; Schumann R
Cochrane Database Syst Rev; 2017 May; 5(5):CD012499. PubMed ID: 28514508
[TBL] [Abstract][Full Text] [Related]
15. Emerging drugs for neuropathic pain.
Gilron I; Dickenson AH
Expert Opin Emerg Drugs; 2014 Sep; 19(3):329-41. PubMed ID: 24793304
[TBL] [Abstract][Full Text] [Related]
16. Oxcarbazepine for neuropathic pain.
Zhou M; Chen N; He L; Yang M; Zhu C; Wu F
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD007963. PubMed ID: 29199767
[TBL] [Abstract][Full Text] [Related]
17. Analgesic efficacy of small-molecule angiotensin II type 2 receptor antagonists in a rat model of antiretroviral toxic polyneuropathy.
Smith MT; Lau T; Wallace VC; Wyse BD; Rice AS
Behav Pharmacol; 2014 Apr; 25(2):137-46. PubMed ID: 24525712
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, placebo-controlled, dose-escalation study: Investigation of the safety, pharmacokinetics, and antihyperalgesic activity of l-4-chlorokynurenine in healthy volunteers.
Wallace M; White A; Grako KA; Lane R; Cato AJ; Snodgrass HR
Scand J Pain; 2017 Oct; 17():243-251. PubMed ID: 29229209
[TBL] [Abstract][Full Text] [Related]
19. Effect of lacosamide in peripheral neuropathic pain: study protocol for a randomized, placebo-controlled, phenotype-stratified trial.
Carmland ME; Kreutzfeldt M; Holbech JV; Andersen NT; Jensen TS; Bach FW; Sindrup SH; Finnerup NB
Trials; 2019 Oct; 20(1):588. PubMed ID: 31604475
[TBL] [Abstract][Full Text] [Related]
20. Amitriptyline for neuropathic pain and fibromyalgia in adults.
Moore RA; Derry S; Aldington D; Cole P; Wiffen PJ
Cochrane Database Syst Rev; 2012 Dec; 12():CD008242. PubMed ID: 23235657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
